#Israel #Jerusalem #Immunotherapy #Scinai #CDMO

Scinai Immunotherapeutics Reports Q1 2025 Financial Results

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), based in Jerusalem, has revealed its financial performance for the first quarter of 2025, concluding March 31. This biopharmaceutical company specializes in developing innovative biological drug candidates, primarily addressing inflammation and immunology-related diseases, alongside offering Contract Development and Manufacturing Organization (CDMO) services through Scinai Bioservices.

The recent financial summary indicates that Scinai generated revenue of $586,000 during the first quarter of 2025. This marks a notable achievement as their CDMO segment initiated revenue generation in mid-2024 and recorded an overall revenue of $658,000 for the complete year of 2024. The increase in revenue during the first quarter is attributed to a growing number of contracts, underscoring the successful expansion of their CDMO operations.

When analyzing research and development (R&D) expenses, Scinai reported costs of $1.296 million for Q1 2025, reflecting a decrease compared to $1.568 million for the same period in the previous year. The decline in expenses is attributed to reduced wages and lower direct R&D costs, a positive sign for the company's financial management during this growth phase.

In terms of marketing and general administrative expenditures, the company reported costs of $500,000 for the first quarter of 2025, which is slightly higher than the $484,000 spent in Q1 2024. This moderate increase indicates the company's intention to continue investing in its growth strategy and operational capabilities.

Financial income for the quarter stood at $11,000, in stark contrast to the financial losses of $231,000 recorded in the same period last year. This improvement can be primarily credited to the conversion of a European Investment Bank (EIB) loan into preferred shares during the third quarter of 2024, showcasing effective financial restructuring.

Despite the positive revenue trajectory, Scinai reported a net loss of $1.557 million for the first quarter of 2025, which is reduced from a net loss of $2.159 million for Q1 2024. This decrease highlights Scinai's ability to manage expenses efficiently while still prioritizing growth initiatives.

As of March 31, 2025, Scinai boasts cash and cash equivalents alongside short-term deposits totaling $1.018 million, a decrease from $1.964 million reported at the end of the same month in 2024. This change highlights the company’s transition in managing its resources amid growing operational commitments.

Scinai Immunotherapeutics not only focuses on developing therapeutic interventions but also operates a CDMO, which facilitates early-stage biotech projects through drug development and clinical trial services. This dual operational approach positions the company uniquely within the biopharmaceutical sector, addressing both internal drug innovation and external manufacturing needs.

Looking Ahead

As Scinai progresses into 2025, its management remains optimistic about both its development pipelines and CDMO business trajectory. However, the company cautions that various risks, including market dynamics and operational uncertainties, could influence future performance outcomes. Regular monitoring of these areas remains essential as Scinai continues to innovate in the biopharmaceutical landscape.

For further information, you can visit their official website.